These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20172739)

  • 21. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.
    Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invariant natural killer T cells and their ligands: focus on multiple sclerosis.
    O'Keeffe J; Podbielska M; Hogan EL
    Immunology; 2015 Aug; 145(4):468-75. PubMed ID: 25976210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [NKT cells: their development, mechanisms and effects of action].
    Bojarska-Junak A; Tabarkiewicz J; Roliński J
    Postepy Hig Med Dosw (Online); 2013 Feb; 67():65-78. PubMed ID: 23475484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid binding orientation within CD1d affects recognition of Borrelia burgorferi antigens by NKT cells.
    Wang J; Li Y; Kinjo Y; Mac TT; Gibson D; Painter GF; Kronenberg M; Zajonc DM
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1535-40. PubMed ID: 20080535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NKT-cell-based immunotherapies in clinical trials.
    Exley MA; Nakayama T
    Clin Immunol; 2011 Aug; 140(2):117-8. PubMed ID: 21592864
    [No Abstract]   [Full Text] [Related]  

  • 26. Fine tuning a well-oiled machine: Influence of NK1.1 and NKG2D on NKT cell development and function.
    Joshi SK; Lang ML
    Int Immunopharmacol; 2013 Oct; 17(2):260-6. PubMed ID: 23800654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unique interplay between sugar and lipid in determining the antigenic potency of bacterial antigens for NKT cells.
    Girardi E; Yu ED; Li Y; Tarumoto N; Pei B; Wang J; Illarionov P; Kinjo Y; Kronenberg M; Zajonc DM
    PLoS Biol; 2011 Nov; 9(11):e1001189. PubMed ID: 22069376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines.
    Faveeuw C; Trottein F
    Cancer Res; 2014 Mar; 74(6):1632-8. PubMed ID: 24599135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut.
    Marrero I; Maricic I; Feldstein AE; Loomba R; Schnabl B; Rivera-Nieves J; Eckmann L; Kumar V
    Front Immunol; 2018; 9():2082. PubMed ID: 30254647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ins and outs of type I iNKT cell development.
    Shissler SC; Webb TJ
    Mol Immunol; 2019 Jan; 105():116-130. PubMed ID: 30502719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycolipid activators of invariant NKT cells as vaccine adjuvants.
    Kharkwal SS; Arora P; Porcelli SA
    Immunogenetics; 2016 Aug; 68(8):597-610. PubMed ID: 27377623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.
    Webb TJ; Bieler JG; Schneck JP; Oelke M
    J Immunol Methods; 2009 Jul; 346(1-2):38-44. PubMed ID: 19446558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innate and adaptive stimulation of murine diverse NKT cells result in distinct cellular responses.
    Tripathi P; Sedimbi SK; Singh AK; Löfbom L; Issazadeh-Navikas S; Weiss S; Förster I; Karlsson MCI; Yrlid U; Kadri N; Cardell SL
    Eur J Immunol; 2019 Mar; 49(3):443-453. PubMed ID: 30427069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural Killer T Cells and Mucosal-Associated Invariant T Cells in Lung Infections.
    Trottein F; Paget C
    Front Immunol; 2018; 9():1750. PubMed ID: 30116242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of invariant natural killer T cells stimulated with microbial α-mannosyl glycolipids.
    Shimamura M; Yamamura M; Nabeshima T; Kitano N; van den Elzen P; Yesilkaya H; Andrew P; Illarionov P
    Sci Rep; 2017 Aug; 7(1):9703. PubMed ID: 28852174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation.
    Kronenberg M
    J Vis Exp; 2007; (10):635. PubMed ID: 18989407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.
    Tripp CH; Sparber F; Hermans IF; Romani N; Stoitzner P
    J Immunol; 2009 Jun; 182(12):7644-54. PubMed ID: 19494288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD1d-unrestricted NKT cells are endowed with a hybrid function far superior than that of iNKT cells.
    Farr AR; Wu W; Choi B; Cavalcoli JD; Laouar Y
    Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12841-6. PubMed ID: 25143585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulation of natural killer T cells by glycolipids.
    Anderson BL; Teyton L; Bendelac A; Savage PB
    Molecules; 2013 Dec; 18(12):15662-88. PubMed ID: 24352021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Harnessing Invariant NKT Cells to Improve Influenza Vaccines: A Pig Perspective.
    Yang G; Richt JA; Driver JP
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29280974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.